Kura Oncology, Inc. (KURA)

NASDAQ: KURA · IEX Real-Time Price · USD
21.33
+0.16 (0.76%)
Mar 28, 2024, 4:00 PM EDT - Market closed

Company Description

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer.

The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.

It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification.

The company was founded in 2014 and is headquartered in San Diego, California.

Kura Oncology, Inc.
Kura Oncology logo
Country United States
Founded 2014
Industry Biotechnology
Sector Healthcare
Employees 142
CEO Dr. Troy Edward Wilson J.D., Ph.D.

Contact Details

Address:
12730 High Bluff Drive, Suite 400
San Diego, California 92130
United States
Phone (858) 500-8800
Website kuraoncology.com

Stock Details

Ticker Symbol KURA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001422143
CUSIP Number 50127T109
ISIN Number US50127T1097
Employer ID 61-1547851
SIC Code 2834

Key Executives

Name Position
Dr. Troy Edward Wilson J.D., Ph.D. Chairman, Chief Executive Officer and President
Kathleen Ford Chief Operating Officer
Dr. Stephen Dale M.D. Chief Medical Officer
Thomas Doyle Senior Vice President of Finance and Accounting
Pete De Spain Executive Vice President of Investor Relations and Corporate Communications
Teresa Brophy Bair Esq., J.D. Chief Legal Officer and Corporate Secretary
Dr. Roger Bakale Ph.D. Senior Vice President of Manufacturing and Supply Chain
Maureen Clancy M.B.A. Vice President and Global Head of Program Leadership and Project Management
Dr. Mollie Leoni M.D. Executive Vice President of Clinical Development
Brian T. Powl M.B.A., M.S. Chief Commercial Officer

Latest SEC Filings

Date Type Title
Feb 29, 2024 UPLOAD Filing
Feb 27, 2024 S-8 Securities to be offered to employees in employee benefit plans
Feb 27, 2024 10-K Annual Report
Feb 27, 2024 8-K Current Report
Feb 15, 2024 424B3 Prospectus
Feb 14, 2024 EFFECT Notice of Effectiveness
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 13, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 13, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals